Global cost modeling analysis of HIV-1 and HCV viral load assays

Tarek Elbeik, Ralph Dalessandro, Yi Ming Arthur Chen, Serguei V. Soutchkov, Richard A. Loftus, Scott Beringer

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

This review addresses hidden costs associated with the Bayer VERSANT® assay, Roche AMPLICOR MONITOR® test and COBAS AMPLICOR MONITOR® test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effective approach for these tests is presented. The analyses demonstrate the need for manufacturers to consider labor and supply costs when marketing a kit in resource-poor countries, noting that marketing strategies need to change. In the absence of any proven monitoring alternative, emphasis is placed on increasing market share to promote significant reduction in kit prices to suit the demands of markets in resource-poor countries. Finally, recommendations are made to improve the overall cost structure of viral load testing. This review is intended as a tool to optimize assay usage in attaining the lowest performance costs by assay and is not to endorse any test, as will become apparent.

Original languageEnglish
Pages (from-to)383-407
Number of pages25
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume3
Issue number4
DOIs
Publication statusPublished - Aug 1 2003
Externally publishedYes

    Fingerprint

Keywords

  • Bayer VERSANT bDNA
  • Center of excellence
  • COBAS
  • Cost model
  • Examples
  • HCV
  • HIV-1
  • Labor and supply costs
  • Resource-poor countries
  • Resource-rich countries
  • Roche AMPLICOR MONITOR

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this